Trial · NCT06942442
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
NCT06942442, Phase 2, Recruiting, Sarcoma Alliance for Research through Collaboration
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma. Trials, record NCT06942442. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06942442
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
- NCT number
- NCT06942442
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 47 participants, estimated
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Conditions
- HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS)
- Interventions
- Physician's Choice, Tebentafusp
- First posted
- 2025-04-24
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Measure Disease Response | Approximately 5.5 months | To estimate the population of HLA-A\*02:01-positive patients with metastatic or unresectable clear cell sarcoma and treated with tebentafusp who are progression free at 24 weeks. PFS (progression-free survival) will be determined using iRECIST. |
| Secondary | Progression-Free Survival | Approximately 5 years | To determine the PFS, in this population at months 3 and 5. Progression-free survival (PFS) defined as the time from study entry to disease relapse, disease progression, or death from any cause, using iRECIST. Patients without an event will be censored at the time of last disease follow-up. |
| Secondary | Estimate Overall Survival | Approximately 5 years | To estimate the overall survival (OS) in patients who are HLA-A\*02:01-positive with metastatic or unresectable clear cell sarcoma and treated with tebentafusp. Overall survival, defined as the time from study entry to death from any cause. Patients who are alive at the time of analysis will be censored at the date of last follow-up. |
| Secondary | Objective Response Rate | Approximately 5 years | To estimate the objective response rate (ORR) in patients who are HLA-A\*02:01-positive with metastatic or unresectable clear cell sarcoma and treated with tebentafusp, according to iRECIST. Objective tumor response, defined as achievement of nadir response of complete response (CR) or partial response (PR) by iRECIST without prior progression any time during protocol therapy. |
| Secondary | Duration of Response | Approximately 5 years | To estimate the duration of response (DoR) in this population. DoR can be defined as the measurement of time from the start of treatment response to disease progression or death |
| Other | Progression-Free Survival and Objective Response Rate | Approximately 5 years | To compare the 5-month PFS rate and ORR for patients who are HLA-A\*02:01-positive with metastatic or unresectable clear cell sarcoma and treated with tebentafusp against patients who are HLA-A\*02:01-negative with metastatic or unresectable clear cell sarcoma, according to RECIST 1.1. Duration of response is defined as the time from a nadir tumor response of CR/PR to disease progression. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06942442
GET https://conductscience.org/api/trials/v1/NCT06942442/registered